Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

asx epn

  • Home
  •  
  • asx epn



  • Most Read
  • Latest Comments
  • Epsilon to provide medicinal cannabis for clinical study in children
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • Epsilon to provide medicinal cannabis for clinical study in children
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • Epsilon to provide medicinal cannabis for clinical study in children
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • Epsilon to provide medicinal cannabis for clinical study in children
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • Epsilon to provide medicinal cannabis for clinical study in children
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • ECS ditches new cartridges to enter vapes and pastilles market
    ECS ditches new cartridges to enter vapes and pastilles market
    • News

  • Vitura declares dividend for the second time amid growing cannabis profits
    Vitura declares dividend for the second time amid growing cannabis profits
    • News

  • Bioxyne makes first sales for mushroom nootropics, a mushroom nootropic brain supplement
    Bioxyne makes first sales for mushroom nootropics, a mushroom nootropic brain supplement
    • News

  • Cann Group strengthens position with variation agreement in medicinal cannabis sector
    Cann Group strengthens position with variation agreement in medicinal cannabis sector
    • News

  • Cann’d: clinical trials show no difference between cannabis capsules and placebo
    Cann’d: clinical trials show no difference between cannabis capsules and placebo
    • News

  • Epsilon to provide medicinal cannabis for clinical study in children
    • News

    Epsilon to provide medicinal cannabis for clinical study in children

    A hot topic in medical research at the moment, medicinal cannabis studies are being carried out for seemingly any and all ailments. One such trial being run by the Murdoch Children’s Research Institute (MCRI) is extending efficacy studies of cannabidiol medicine to children with intellectual disability that exhibit severe behavioural problems. To facilitate these studies,

    Read More
    Public
  • Epsilon Healthcare expands medicinal cannabis telehealth to in-clinic locations
    • News

    Epsilon Healthcare expands medicinal cannabis telehealth to in-clinic locations

    Having developed a thriving telehealth business that has seen significant uptake from patients seeking medicinal cannabis solutions, Epsilon Healthcare (ASX: EPN) is set to expand into retail locations for in-clinic consultations.  While the progressive healthcare provider moves in the opposite direction to other medical clinics which were forced to adopt telehealth during the pandemic, telehealth

    Read More
    Public

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.